$THC

KERREY J ROBERT sold $160K of THC

KERREY J ROBERT sold 905 shares of TENET HEALTHCARE CORP (THC) at $176.89 ($0.16M total) on 2026-05-28.

Original reporting
SEC EDGAR · KERREY J ROBERT
Published May 30, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 30, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The incremental information is the disclosed sale details (date, shares, price, post-transaction holdings). Without accompanying corporate news, the impact is mainly sentiment/positioning rather than fundamentals.

02

Market read

Traders may monitor for follow-on insider activity or any concurrent company-specific catalysts, but this filing by itself is unlikely to reset valuation.

03

What to watch

No 10b5-1 plan is indicated, but the filing alone doesn’t reveal whether the sale was planned, tax-related, or driven by personal liquidity needs; size relative to holdings (17,165 after sale) matters for interpretation.

Relevance 6/10Novelty 6/10Timing: After SEC Form 4 filing/disclosure (filed 2026-05-29; sale dated 2026-05-28)

Background

SEC Form 4 reports insider transactions for Tenet Healthcare; this disclosure covers a director’s open-market sale.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director KERREY J ROBERT sold 905 shares in an open-market transaction on 2026-05-28 at $176.89/share.

Expected impact

Low-to-mild negative drift possible around the disclosure, but no clear directional catalyst from the filing alone.

Evidence & confidence

The filing is an insider transaction without a 10b5-1 plan and provides a concrete sale price/size; however, insider sales are often routine and typically have limited causal linkage to near-term fundamentals.

Market effects

Minimal; this is company-specific insider activity with no stated operational/regulatory change.

None indicated.

None indicated.

Counterpoint

Because the sale is only 905 shares and not tied to a disclosed corporate event, the market may treat it as diversification or routine liquidity rather than bearish information.

Key entities

  • TENET HEALTHCARE CORP

    Subject of the SEC Form 4 insider transaction disclosure.

  • KERREY J ROBERT

    Director who sold 905 shares of THC on 2026-05-28.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

$THCMedAI 8/10

Tenet Healthcare at Wells Fargo conference: high-acuity push deepens

Tenet Healthcare (THC) presented at the Wells Fargo Healthcare Conference, outlining a strategy focused on high-acuity care, capital spending, and cost control. The company raised full-year guidance, citing volume growth and cost discipline. Shares are near their 52-week high at $268.82, up over 30% year-to-date. Tenet expects continued pressure in some payer channels and near-term earnings drag from Conifer's transition. Management plans to invest in complex procedures and maintain capital spen